Pulmonary embolism (PE) is one of the leading causes of cardiovascular mortality, with a high 30-day mortality rate. Despite clear treatment guidelines based on patient risk profiles, evidence suggests a discrepancy between clinical practice worldwide and the recommendations outlined in these guidelines. This deviation is often due to the comorbidities present in patients with PE, which complicate management decisions. As a result, alongside traditional standard-of-care treatments, novel emerging therapies are being explored to address these challenges. This review aims to provide an overview of the current epidemiology, initial assessment strategies, conventional treatment options, and emerging therapeutic approaches for PE.